Menu
Search for
Log In
Topics
AI & Technology
Agentic
Analytics
Automation
Blockchain
Cloud
Computer Vision
Conversational AI
Cyber Security
Data
Digital Transformation
Ethics & Responsibility
Future of AI
IoT
Machine Learning
Metaverse
Natural Language Processing (NLP)
Responsible AI
Robotics
Sectors & Use Cases
Automotive
Education
Energy
Finance
Gaming
Healthcare
Insurance
Manufacturing
Property & Real Estate
Public Sector
Retail
Sports
Supply Chain & Logistics
Telecommunications
AI Business Strategy
Digital Transformation
Environment & Sustainability
Ethics & Responsibility
HR, Workforce, and Skills
Legal & Compliance
Marketing & Customer
Product & Revenue
Policy & Regulation
AI Leadership & Perspective
Boardroom & Governance
C-Suite Perspective
Community Voices
Founder & Investor Voices
Innovation Spotlight
Interview
Leadership Vision
Strategic Partnerships
Columnists
The Control Layer By Victor Dey
Learn
Events
Newsletter
Reports & Guides
Webinars
Media Kit
Premium
Login
Contact Us
Search for
Home
/
Press release
Press release
Press Release
Cision PR Newswire
20 April 2026
SKYWORTH Dominates the 139th Canton Fair with Revolutionary OLED, RGB, and QD-MiniLED Smart TVs, Redefining Global Display Technology
Read More »
Press Release
Cision PR Newswire
20 April 2026
IGT Appoints Mark Wadley Incoming President of Land-Based Gaming
Read More »
Cision PR Newswire
20 April 2026
SOLAI Limited Files 2025 Annual Report on Form 20-F
Read More »
Press Release
Cision PR Newswire
20 April 2026
U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Read More »
Business Wire
20 April 2026
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer
Read More »
Business Wire
20 April 2026
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer
Read More »
Business Wire
20 April 2026
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer
Read More »
Press Release
Cision PR Newswire
20 April 2026
Milvus Robotics Introduces the SEIT F1500S Forklift-Type Autonomous Mobile Robot for Advanced Material Handling
Read More »
Cision PR Newswire
20 April 2026
Daqo New Energy Files Annual Report on Form 20-F for Fiscal Year 2025
Read More »
Business Wire
20 April 2026
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer
Read More »
Previous page
Next page
Back to top button
Close
Search for
Close
Search for
Close
Log In
Forget?
Remember me
Log In
